The manufacturer of Strattera is Eli Lilly and Company [1].
Who else makes Strattera?
While Eli Lilly and Company is the originator, other companies may manufacture or market generic versions of atomoxetine, the active ingredient in Strattera, once patents and exclusivity expire [2].
When did Strattera get approved?
Strattera (atomoxetine) was approved by the U.S. Food and Drug Administration (FDA) in 2002 [3].
What are the side effects of Strattera?
Common side effects of Strattera can include stomach upset, decreased appetite, nausea, vomiting, fatigue, dizziness, and mood swings [4]. Serious side effects are rare but can include liver problems and, in some children and adolescents, an increased risk of suicidal thoughts or behaviors [4][5]. Patients experiencing new or worsening depression, unusual changes in behavior, or suicidal thoughts should contact their doctor immediately [5].
How does Strattera work?
Strattera is a non-stimulant medication that works by increasing the levels of a neurotransmitter called norepinephrine in the brain [6]. Norepinephrine plays a role in attention and impulse control [6]. It is believed to help improve focus and reduce impulsive behaviors associated with Attention-Deficit/Hyperactivity Disorder (ADHD) [6].
What is the active ingredient in Strattera?
The active ingredient in Strattera is atomoxetine [2].
What other drugs are similar to Strattera?
Other medications used to treat ADHD include stimulants like Adderall and Ritalin, as well as other non-stimulant options such as Intuniv (guanfacine extended-release) and Kapvay (clonidine extended-release) [7]. The choice of medication depends on individual patient needs, medical history, and response to treatment [7].
Where can I find more information on Strattera patents?
Information regarding patents for Strattera and its active ingredient, atomoxetine, can be found on resources like DrugPatentWatch.com [2]. This site tracks patent expirations and can provide details on intellectual property related to pharmaceutical drugs.